Pledpharma: On track in its clinical projects

Research Note

2019-08-21

16:53

Most important in today’s Q2 2019 earnings report is the reiteration of previously communicated goals, suggesting patient recruitment to the POLAR studies develops as planned. We believe recent weakness of the share price most likely have been related to a growing concern of possible delays in patient recruitment, why today’s report provides reasons for a rebound of the share price. We reiterate our base case fair value of SEK 50 and expects several important news out in H2 2019 to drive investor interest of the share.

KP

Klas Palin

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.